» Articles » PMID: 34615582

The Burden and Determinants of Post-TB Lung Disease

Overview
Specialty Pulmonary Medicine
Date 2021 Oct 7
PMID 34615582
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Post-TB lung disease (PTLD) is an important but under-recognised chronic respiratory disease in high TB burden settings such as Tanzania. This was a cross-sectional survey of adults within 2 years of completion of TB treatment in Kilimanjaro, Tanzania. Data were collected using questionnaires (symptoms and exposures), spirometry and chest radiographs to assess outcome measures, which were correlated with daily life exposures, including environment and diet. Of the 219 participants enrolled (mean age: 45 years ± 10; 193 88% males), 98 (45%) reported chronic respiratory symptoms; 46 (22%) had received treatment for TB two or more times; and HIV prevalence was 35 (16%). Spirometric abnormalities were observed in 146 (67%). Chest X-ray abnormalities occurred in 177 (86%). A diagnosis of PTLD was made in 200 (91%), and half had clinically relevant PTLD. The prevalence of mMRC ≥Grade 3 chronic bronchitis and dyspnoea was respectively 11% and 26%. Older age, multiple episodes of TB and poverty indicators were linked with clinically relevant PTLD. We found a substantial burden of PTLD in adults who had recently completed TB treatment in Tanzania. There is a pressing need to identify effective approaches for both the prevention and management of this disease.

Citing Articles

Economic burden of chronic obstructive pulmonary disease and post-tuberculosis sequelae in low- and middle-income countries: a database compiled from a systematic review and meta-analysis.

Lin Y, Walker A, Batta M, Ottilie-Kovelman S, Duchenko A, Brugger C BMJ Public Health. 2025; 2(1):e000441.

PMID: 40018115 PMC: 11816951. DOI: 10.1136/bmjph-2023-000441.


The prevalence and pattern of post tuberculosis lung disease including pulmonary hypertension from an Australian TB service; a single-centre, retrospective cohort study.

Byrne A, Al-Hindawi Y, Plit M, Yeung L, Rigava S, King M BMC Pulm Med. 2025; 25(1):84.

PMID: 39984904 PMC: 11846343. DOI: 10.1186/s12890-025-03549-5.


"You find yourself in a very humiliating situation": experiences of people living with post-tuberculosis lung disease in Brazil.

de Almeida C, Furin J, Sumiya A, Silva D, Mitnick C Front Public Health. 2025; 12():1431881.

PMID: 39776473 PMC: 11703962. DOI: 10.3389/fpubh.2024.1431881.


Prevalence of TB-related symptoms and self-reported disability among adult TB survivors.

McDonald A, Nakkonde D, Kaggwa P, Zalwango S, Joseph A, Buregyeya E IJTLD Open. 2024; 1(12):540-546.

PMID: 39679208 PMC: 11636498. DOI: 10.5588/ijtldopen.24.0141.


Risk factors associated with post-tuberculosis sequelae: a systematic review and meta-analysis.

Akalu T, Clements A, Liyew A, Gilmour B, Murray M, Alene K EClinicalMedicine. 2024; 77:102898.

PMID: 39502524 PMC: 11535315. DOI: 10.1016/j.eclinm.2024.102898.


References
1.
Romanowski K, Baumann B, Basham C, Khan F, Fox G, Johnston J . Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019; 19(10):1129-1137. DOI: 10.1016/S1473-3099(19)30309-3. View

2.
. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020; 8(6):585-596. PMC: 7284317. DOI: 10.1016/S2213-2600(20)30105-3. View

3.
Ahmed R, Robinson R, Mortimer K . The epidemiology of noncommunicable respiratory disease in sub-Saharan Africa, the Middle East, and North Africa. Malawi Med J. 2017; 29(2):203-211. PMC: 5610297. DOI: 10.4314/mmj.v29i2.24. View

4.
Almagro P, Martinez-Camblor P, Soriano J, Marin J, Alfageme I, Casanova C . Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. PLoS One. 2014; 9(2):e89866. PMC: 3937394. DOI: 10.1371/journal.pone.0089866. View

5.
Gingo M, He J, Wittman C, Fuhrman C, Leader J, Kessinger C . Contributors to diffusion impairment in HIV-infected persons. Eur Respir J. 2013; 43(1):195-203. PMC: 4023348. DOI: 10.1183/09031936.00157712. View